loader

cse:lxx

LATEST ARTICLES
THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

THE FOCUS DOCTRINE: 5 Assets Securing the 2026 Biological Choke Point

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Latest News

More News

Outlook Reports world

Resource
Tech
Life Science

Browse Companies

Resource
Tech
Life Science
MARKETS
COMMODITIES
CURRENCIES